
Oncopeptides Q2 2024 - Strong Q/Q Sales Growth

Redeye comments on Oncopeptides' Q2 report 2024, with a Q/Q sales growth of 60%, which was above our estimates.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Oncopeptides Q2 2024 - Strong Q/Q Sales Growth](#)